BAFNAPH.NSE · Bafna Pharmaceuticals Limited

-

Please sign in to comment on BAFNAPH.NSE

1 Comment

Admin

4 years ago

Bafna Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 0.2% above its 200 day moving average.

From a valuation standpoint, the stock is 1.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.7.

Bafna Pharmaceuticals Limited's total revenue rose by 44.4% to $167M since the same quarter in the previous year.

Its net income has increased by 428.8% to $18M since the same quarter in the previous year.

Based on the above factors, Bafna Pharmaceuticals Limited gets an overall score of 4/5.

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
ISIN	INE878I01022
Exchange	NSE
CurrencyCode	INR

Beta	0.47
Market Cap	2B
PE Ratio	44.18
Target Price	None
Dividend Yield	None

ABOUT

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, and internationally. The company was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited operates as a subsidiary of SRJR Lifesciences LLP.

BAFNAPH.NSE · Bafna Pharmaceuticals Limited

-

Bafna Pharmaceuticals Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Bafna Pharmaceuticals Limited using a moving average strategy